Skip to main content

Loading market data...

GMED

Globus Medical, Inc.

NYSE • United states

$78.96

+$3.31

(+4.38%)

Source: Yahoo Finance · Quote time Oct 20, 2026 20:00 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Globus Medical, Inc. (GMED)

Unavailable

Quotes may be delayed

$10.60B

Market Cap

1,545,304

Volume

19.8

P/E Ratio

Unavailable

Div Yield

Globus Medical, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

6 Aug 2026

Globus Medical, Inc. filed Form 10-Q

Globus Medical, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

6 Aug 2026

Globus Medical, Inc. reported Operating or financial results

Globus Medical, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

4 Jun 2026

Globus Medical, Inc. reported A director or senior management change or compensation event

Globus Medical, Inc. filed an 8-K covering a director or senior management change or compensation event, shareholder voting results, supporting financial statements or exhibits.

7 May 2026

Globus Medical, Inc. filed Form 10-Q

Globus Medical, Inc. submitted Form 10-Q to the SEC for the period ending Mar 31, 2026.

7 May 2026

Globus Medical, Inc. reported Operating or financial results

Globus Medical, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$507.75M

Total assets (USD)$5.49B

Total liabilities (USD)$719.66M

Shareholders' equity (USD)$4.77B

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$789.61M	$182.43M	$151.57M	$1.10	10-Q · 6 Aug 2026
Q1 2026	$759.85M	$150.39M	$124.30M	$0.90	10-Q · 7 May 2026
Q4 2025	$826.42M	$169.34M	$140.59M	Unavailable	10-K · 24 Feb 2026
Q3 2025	$769.05M	$137.36M	$118.97M	$0.88	10-Q · 6 Nov 2025
Q2 2025	$745.34M	$76.11M	$202.85M	$1.49	10-Q · 7 Aug 2025
Q1 2025	$598.12M	$97.00M	$75.46M	$0.54	10-Q · 8 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $98.75

25.1% upside potential

📈

Strong Buy

Unavailable

👍

Buy

9

⏸️

Hold

4

📉

Sell

0

13 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 10:49 UTC Targets range 82.00–117.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

15

Sep 2026

TOBIN JAMES R

Director

Option exercise

$58.72 per share

30,000 shares

15

Sep 2026

TOBIN JAMES R

Director

Open-market sale

$74.58 per share

30,000 shares

18

Aug 2026

ZARRILLI STEPHEN T

Director

Option exercise

$53.27 per share

25,000 shares

18

Aug 2026

ZARRILLI STEPHEN T

Director

Open-market sale

$87.04 per share

25,000 shares

27

Jul 2026

Davidar David D

Director

Gift

Unavailable per share

2,500 shares

5

Jun 2026

Davidar David D

Director

Option exercise

$26.27 per share

25,000 shares

5

Jun 2026

Davidar David D

Director

Open-market sale

$80.76 per share

25,000 shares

4

Jun 2026

RHOADS ANN D

Director

Option exercise

$26.27 per share

25,000 shares

25

Feb 2026

Huller Kelly

EVP, GC, Corporate Secretary

Option exercise

$43.58 per share

20,000 shares

25

Feb 2026

Huller Kelly

EVP, GC, Corporate Secretary

Open-market sale

$94.50 per share

20,000 shares

Top Shareholders

Blackrock, Inc.

10,806,724 shares

2.947% change

6/30/2026

Vanguard Group Inc

10,549,455 shares

-0.531% change

12/31/2025

Jupiter Topco Llc

8,200,423 shares

New% change

6/30/2026

Janus Henderson Group Ltd.

7,623,095 shares

4.499% change

3/31/2026

Vanguard Capital Management Llc

5,107,532 shares

1.486% change

6/30/2026

Vanguard Portfolio Management Llc

4,994,385 shares

2.355% change

6/30/2026

Invesco Ltd.

4,309,771 shares

-0.159% change

6/30/2026

Kayne Anderson Rudnick Investment Management Llc

4,279,730 shares

New% change

6/30/2026

State Street Corp

3,714,029 shares

3.444% change

6/30/2026

Sculptor Capital Lp

3,000,000 shares

-1.897% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 10:49 UTC· 21 hours ago

Research coverage and investment tools

Globus Medical, Inc. (GMED) is a stock listed on the New York Stock Exchange in the United States, in the Health Care sector (Medical/Dental Instruments). Its last price was US$78.96 on 20 Oct 2026. That is 46% of the way from its 52-week low of US$59.51 to its 52-week high of US$101.40. Its market capitalisation was US$10.6 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$789.61M	$182.43M	$151.57M	$1.10	—	23.1%	$176.57M	10-Q · 6 Aug 2026 (opens in a new tab)
Q1 2026	$759.85M	$150.39M	$124.30M	$0.90	—	19.8%	$162.75M	10-Q · 7 May 2026 (opens in a new tab)
Q4 2025	$826.42M	$169.34M	$140.59M	Unavailable	—	20.5%	$202.39M	10-K · 24 Feb 2026 (opens in a new tab)
Q3 2025	$769.05M	$137.36M	$118.97M	$0.88	—	17.9%	$213.88M	10-Q · 6 Nov 2025 (opens in a new tab)
Q2 2025	$745.34M	$76.11M	$202.85M	$1.49	—	10.2%	$31.30M	10-Q · 7 Aug 2025 (opens in a new tab)
Q1 2025	$598.12M	$97.00M	$75.46M	$0.54	—	16.2%	$141.20M	10-Q · 8 May 2025 (opens in a new tab)

Cash and equivalents: $507.75M
Total assets: $5.49B
Total liabilities: $719.66M
Shareholders' equity: $4.77B

10-Q · 6 Aug 2026

Globus Medical, Inc. filed Form 10-Q (opens in a new tab)

Globus Medical, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 6 Aug 2026

Globus Medical, Inc. reported Operating or financial results (opens in a new tab)

Globus Medical, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
8-K · 4 Jun 2026 · Management change

Globus Medical, Inc. reported A director or senior management change or compensation event (opens in a new tab)

Globus Medical, Inc. filed an 8-K covering a director or senior management change or compensation event, shareholder voting results, supporting financial statements or exhibits.
10-Q · 7 May 2026

Globus Medical, Inc. filed Form 10-Q (opens in a new tab)

Globus Medical, Inc. submitted Form 10-Q to the SEC for the period ending Mar 31, 2026.
8-K · 7 May 2026

Globus Medical, Inc. reported Operating or financial results (opens in a new tab)

Globus Medical, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

Insider	Date	Transaction	Shares	Average price	Filing
TOBIN JAMES R Director	15 Sep 2026	Option exercise (M)	+30,000	$58.72	Form 4 (opens in a new tab)
TOBIN JAMES R Director	15 Sep 2026	Open-market sale (S)	−30,000	$74.58	Form 4 (opens in a new tab)
ZARRILLI STEPHEN T Director	18 Aug 2026	Option exercise (M)	+25,000	$53.27	Form 4 (opens in a new tab)
ZARRILLI STEPHEN T Director	18 Aug 2026	Open-market sale (S)	−25,000	$87.04	Form 4 (opens in a new tab)
Davidar David D Director	27 Jul 2026	Gift (G)	−2,500	—	Form 4 (opens in a new tab)
Davidar David D Director	5 Jun 2026	Option exercise (M)	+25,000	$26.27	Form 4 (opens in a new tab)
Davidar David D Director	5 Jun 2026	Open-market sale (S)	−25,000	$80.76	Form 4 (opens in a new tab)
RHOADS ANN D Director	4 Jun 2026	Option exercise (M)	+25,000	$26.27	Form 4 (opens in a new tab)
Huller Kelly EVP, GC, Corporate Secretary	25 Feb 2026	Option exercise (M)	+20,000	$43.58	Form 4 (opens in a new tab)
Huller Kelly EVP, GC, Corporate Secretary	25 Feb 2026	Open-market sale (S)	−20,000	$94.50	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Blackrock, Inc.	6/30/2026	10,806,724	2.947%
Vanguard Group Inc	12/31/2025	10,549,455	-0.531%
Jupiter Topco Llc	6/30/2026	8,200,423	New
Janus Henderson Group Ltd.	3/31/2026	7,623,095	4.499%
Vanguard Capital Management Llc	6/30/2026	5,107,532	1.486%
Vanguard Portfolio Management Llc	6/30/2026	4,994,385	2.355%
Invesco Ltd.	6/30/2026	4,309,771	-0.159%
Kayne Anderson Rudnick Investment Management Llc	6/30/2026	4,279,730	New
State Street Corp	6/30/2026	3,714,029	3.444%
Sculptor Capital Lp	6/30/2026	3,000,000	-1.897%

Previous close: 75.65 USD
Day range: 76.17 – 79.20 USD
52-week range: 59.51 – 101.40 USD
Volume: 1,545,304
Market cap: $10.60B
Average volume: 875,720
P/E ratio: 19.8
EPS (FY 2025, diluted): 3.92 USD
Shares outstanding: 134.26M
Beta (5Y monthly): 0.96

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 20:00 UTC· 1 day ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:21 UTC· 1 hour ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for GMED yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.